Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 24;17(1):17.
doi: 10.1186/s40644-017-0119-3.

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Geethal N Malalagama  1 , Steve Chryssidis  2 , Francis X Parnis  3
Affiliations

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Geethal N Malalagama et al. Cancer Imaging. .

Abstract

Background: Haematuria and pelvic pain are recognized and documented adverse reactions related to Cabazitaxel use. To date there has not been any documentation of imaging findings in patients with this presentation.

Cases: We report a case series of five patients who experienced these symptoms while on Cabazitaxel and were all found to have very similar urothelial changes on CT. The patients were noted to have ureteric and renal pelvic dilatation along with urothelial enhancement (in those who had post contrast imaging). All of these changes were noted to be reversible in those who had follow up imaging after cessation of Cabazitaxel and initiation of a short course of steroids.

Conclusion: This case series helps demonstrate the pathological reversible urothelial inflammatory changes that may be occurring in patients experiencing haematuria and pelvic pain on Cabazitaxel therapy. These changes may relate to direct toxic effect of drug metabolites, a radiation recall type phenomenon or a combination of both.

Keywords: Cabazitaxel; Dysuria; Haematuria; Pain; Pelvic.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Coronal images of the left renal collecting system during Cabazitaxel treatment (right) shows significant dilatation and urothelial enhancement compared to pre Cabazitaxel treatment images (left)
Fig. 2
Fig. 2
Coronal images of the right kidney (top left) and bilateral ureters (bottom left - green arrows) during Cabazitaxel therapy show dilatation compared to pre Cabazitaxel treatment (top and bottom right)
Fig. 3
Fig. 3
Coronal images of both kidneys (top left) and ureters (bottom left - green arrows) during Cabazitaxel therapy shows dilatation and urothelial enhancement. These changes have completely resolved 3 months after cessation of Cabazitaxel (top and bottom right)
Fig. 4
Fig. 4
Coronal images of the right kidney (top left) and left kidney (bottom left) during Cabazitaxel therapy shows dilatation and urothelial enhancement. These changes had completely resolved at 5 months after Cabazitaxel cessation (top and bottom right)
Fig. 5
Fig. 5
Coronal images of both kidneys (top left) and ureters (bottom left - green arrows) during Cabazitaxel treatment shows dilatation of the right ureter and renal pelvis with urothelial enhancement. The left ureter and renal pelvis appear unremarkable. Changes involving the right urothelium are most apparent when compared to pre Cabazitaxel treatment images of the kidneys (top right) and ureters (bottom right - green arrows)
See this image and copyright information in PMC

References

    1. Jevtana (Cabazitaxel) TGA approved product information. Macquarie Park New South Wales: Sanofi-aventis Australia. Approved 8th December 2011.
    1. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59(3):237–245. doi: 10.1016/S0167-8140(01)00328-0. - DOI - PubMed
    1. Azria D, Magné N, Zouhair A, Castadot P, Culine S, Ychou M, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev. 2005;31(7):555–570. doi: 10.1016/j.ctrv.2005.07.008. - DOI - PubMed
    1. Sebastian de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/S0140-6736(10)61389-X. - DOI - PubMed
    1. Diéras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A. Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer. 2013;49(1):25–34. doi: 10.1016/j.ejca.2012.07.008. - DOI - PubMed